Though the full impact of a recent federal court ruling is unclear, doctors can expect more off-label drug use information from drug manufacturers.
Washington — Eli Lilly announced this month that it would direct its sales representatives to market its osteoporosis drug, Evista (raloxifene), as a breast cancer prevention agent.
This step was noteworthy for two reasons. First, Evista so far has gained Food and Drug Administration marketing approval only for its osteoporosis indication. Second, a July court order barred the company from promoting the off-label breast cancer prevention use.
Source: American Medical News
Go There(Click to read the entire article)
planetc1.com-news @ 09:57 | Article ID: 935074643